Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Guardant Health stock

GH
US40131M1099
A2N5RY

Price

38.66
Today +/-
+1.90
Today %
+5.18 %

Guardant Health stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Guardant Health stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Guardant Health stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Guardant Health stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Guardant Health's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Guardant Health Stock Price History

DateGuardant Health Price
1/10/202538.66 undefined
1/10/202536.71 undefined
1/8/202536.59 undefined
1/7/202536.15 undefined
1/6/202535.88 undefined
1/3/202533.76 undefined
1/2/202531.77 undefined
12/31/202430.55 undefined
12/30/202430.54 undefined
12/27/202430.44 undefined
12/26/202431.37 undefined
12/24/202431.57 undefined
12/23/202431.04 undefined
12/20/202431.67 undefined
12/19/202431.13 undefined
12/18/202432.36 undefined
12/17/202434.84 undefined
12/16/202435.62 undefined
12/13/202434.76 undefined

Guardant Health Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Guardant Health, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Guardant Health from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Guardant Health’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Guardant Health. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Guardant Health’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Guardant Health’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Guardant Health’s growth potential.

Guardant Health Revenue, EBIT and net profit per share

DateGuardant Health RevenueGuardant Health EBITGuardant Health Net Income
2029e2.15 B undefined105.24 M undefined287.6 M undefined
2028e1.5 B undefined-187.61 M undefined-25.45 M undefined
2027e1.29 B undefined-302.89 M undefined-43.27 M undefined
2026e1.05 B undefined-310.98 M undefined-297.66 M undefined
2025e871.59 M undefined-387.13 M undefined-372.63 M undefined
2024e745.6 M undefined-424.2 M undefined-436.67 M undefined
2023563.95 M undefined-564.73 M undefined-479.45 M undefined
2022449.5 M undefined-544.4 M undefined-654.6 M undefined
2021373.7 M undefined-411 M undefined-405.7 M undefined
2020286.7 M undefined-255 M undefined-253.8 M undefined
2019214.4 M undefined-82.4 M undefined-75.7 M undefined
201890.6 M undefined-93 M undefined-85.1 M undefined
201749.8 M undefined-76.6 M undefined-89 M undefined
201625.2 M undefined-43.8 M undefined-46.1 M undefined

Guardant Health Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.030.050.090.210.290.370.450.560.750.871.051.291.52.15
-96.0083.67137.7833.6430.4220.3825.3932.3316.9120.5523.0516.4142.75
12.0036.7352.2266.8267.8367.2965.2659.6845.1038.5832.0026.0122.3415.65
31847143194251293336000000
-46-89-85-75-253-405-654-479-436-372-297-43-25287
-93.48-4.49-11.76237.3360.0861.48-26.76-8.98-14.68-20.16-85.52-41.86-1,248.00
83.683.685.890.697.5101.3102.2111.99000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Guardant Health Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Guardant Health is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
0.10.220.420.521.790.931.011.17
3.512.835.74853.397.797.388.78
00000000
2.87.39.115.222.730.751.661.95
1.61.55.211.417.553.131.527.74
0.10.240.470.61.891.111.191.35
12.6163172.8100.1313.9341.9302.71
073.377.6268.8246.669800
00000000
0008.516.214.211.78.98
0003.33.33.33.33.29
0.810.79.811.817.360.961.5124.33
0.010.10.120.370.381.090.420.44
0.120.340.590.962.272.21.611.79
               
180500000000
0.0100.761.151.91.661.742.3
-107.6-195.7-280.8-352.8-606.6-1,007.8-1,662.4-2,141.86
00000000
-0.1-0.5-0.11.12.7-4.8-19.5-3.68
0.080.310.480.81.30.650.060.16
3.2510.616.27.317.668.951.74
410.418.641.246.383.6106.9136.21
7417.615.313.293.517.417.97
00000000
10020010000000
14.319.646.972.766.8194.7193.2205.92
0.020000.811.131.141.14
00000000
5.714.215.441.843.1230219.2281.85
0.020.010.020.040.851.361.361.42
0.040.030.060.110.921.561.551.63
0.120.340.550.912.212.21.611.79
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Guardant Health provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Guardant Health's financial health and stability.

Assets

Guardant Health's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Guardant Health must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Guardant Health after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Guardant Health's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-46-83-84-67-246-384-654-479
3571116223542
00000000
2-4-1-6-47-406153
5141232318345342148
21110000
0000001,0001,000
-36-72-72-47-103-209-309-324
-1-6-20-21-54-75-77-20
26-170-153-317-617-63149840
27-163-132-296-56311227860
00000000
0-0.03001.13000
403072563683721711503
0.040.280.290.371.41-0.07-0.190.48
0036-1-94-83-200-26
00000000
2939672689-340-350991
-38.48-78.92-92.39-68.35-157.99-284.06-386.92-345.46
00000000

Guardant Health stock margins

The Guardant Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Guardant Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Guardant Health.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Guardant Health's sales revenue. A higher gross margin percentage indicates that the Guardant Health retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Guardant Health's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Guardant Health's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Guardant Health's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Guardant Health. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Guardant Health's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Guardant Health Margin History

Guardant Health Gross marginGuardant Health Profit marginGuardant Health EBIT marginGuardant Health Profit margin
2029e59.74 %4.9 %13.4 %
2028e59.74 %-12.47 %-1.69 %
2027e59.74 %-23.44 %-3.35 %
2026e59.74 %-29.62 %-28.35 %
2025e59.74 %-44.42 %-42.75 %
2024e59.74 %-56.89 %-58.57 %
202359.74 %-100.14 %-85.02 %
202265.38 %-121.11 %-145.63 %
202167.27 %-109.98 %-108.56 %
202067.74 %-88.94 %-88.52 %
201967.02 %-38.43 %-35.31 %
201852.32 %-102.65 %-93.93 %
201736.55 %-153.82 %-178.71 %
201612.3 %-173.81 %-182.94 %

Guardant Health Stock Sales Revenue, EBIT, Earnings per Share

The Guardant Health earnings per share therefore indicates how much revenue Guardant Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Guardant Health earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Guardant Health's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Guardant Health’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Guardant Health's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Guardant Health Revenue, EBIT and net profit per share

DateGuardant Health Sales per ShareGuardant Health EBIT per shareGuardant Health Earnings per Share
2029e17.38 undefined0 undefined2.33 undefined
2028e12.18 undefined0 undefined-0.21 undefined
2027e10.46 undefined0 undefined-0.35 undefined
2026e8.5 undefined0 undefined-2.41 undefined
2025e7.05 undefined0 undefined-3.02 undefined
2024e6.03 undefined0 undefined-3.53 undefined
20235.04 undefined-5.04 undefined-4.28 undefined
20224.4 undefined-5.33 undefined-6.41 undefined
20213.69 undefined-4.06 undefined-4 undefined
20202.94 undefined-2.62 undefined-2.6 undefined
20192.37 undefined-0.91 undefined-0.84 undefined
20181.06 undefined-1.08 undefined-0.99 undefined
20170.6 undefined-0.92 undefined-1.06 undefined
20160.3 undefined-0.52 undefined-0.55 undefined

Guardant Health business model

Guardant Health Inc is an American company specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specialized in the development of blood tests for pregnancies. Guardant Health's goal is to detect traces of cancer cells in the blood of patients to enable early cancer diagnosis. Based on the liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without relying on invasive methods such as tissue sampling. This allows for faster diagnosis and quicker treatment decision-making. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can aid in cancer identification, as well as tests that can help doctors monitor the success of cancer therapies. Guardant Health has directed its offerings towards multiple products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to cancer diagnosis and treatment. Guardant360 is a diagnostic test specifically developed to help doctors sequence the DNA of cancer cells in the blood of patients and identify the genetic changes contributing to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It enables a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can aid in tracking disease progression and selecting appropriate therapies. GuardantReveal is a test aimed at monitoring patients at higher risk of cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, more than 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is based in Redwood City, California, and employs over 1,000 employees. It has a broad investor base, including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in funding. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company aims to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health is one of the most popular companies on Eulerpool.com.

Guardant Health SWOT Analysis

Strengths

1. Proprietary liquid biopsy technology: Guardant Health Inc has developed advanced liquid biopsy technology, which allows for non-invasive genetic testing and enables early detection of cancer and other diseases.

2. Strong brand reputation: Guardant Health has established a strong brand reputation within the healthcare industry for its innovative and reliable diagnostic tests.

3. Strategic partnerships: The company has formed strategic partnerships with leading pharmaceutical companies and research institutions, enhancing its market presence and access to resources.

Weaknesses

1. Reliance on key customers: Guardant Health Inc may face risks due to its dependence on a few key customers for a significant portion of its revenue, making its financial performance vulnerable to changes in customer demand or preferences.

2. High research and development costs: Developing and improving liquid biopsy technology requires significant investment in research and development, which might strain the company's financial resources.

3. Regulatory challenges: As a healthcare company dealing with genetic testing and diagnostic tools, Guardant Health Inc is subject to stringent regulations, which may delay product approvals or limit market expansion.

Opportunities

1. Growing demand for precision medicine: With the increasing emphasis on personalized treatment approaches, Guardant Health Inc is well-positioned to benefit from the rising demand for precision medicine and targeted therapies.

2. Expansion into international markets: Guardant Health Inc can explore opportunities to expand its presence in international markets, where there is an increasing need for advanced genetic testing and improved cancer diagnostics.

3. Potential for partnerships with insurance providers: Collaborating with insurance providers to incorporate genetic testing as part of routine healthcare coverage could expand the customer base for Guardant Health Inc.

Threats

1. Competitive landscape: The market for liquid biopsy and genetic testing is highly competitive, with the presence of established players as well as emerging startups. Guardant Health Inc may face intense competition, which could impact market share and pricing.

2. Legal and ethical concerns: The use of genetic testing can raise privacy and ethical concerns. Guardant Health Inc needs to effectively address these issues to avoid potential legal challenges and maintain customer trust.

3. Economic downturn and healthcare industry changes: Guardant Health Inc's financial performance can be influenced by economic downturns and fluctuations in the healthcare industry, which might affect funding and reimbursement policies.

Guardant Health Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Guardant Health Revenue by Segment

DateInternationalUnited States
202337.42 M USD526.52 M USD
202228.92 M USD420.62 M USD
202121.09 M USD352.56 M USD
202022.07 M USD264.66 M USD
201920.06 M USD194.31 M USD
201812.72 M USD77.92 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Guardant Health Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Guardant Health historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Guardant Health shares outstanding

The number of shares was Guardant Health in 2024 — This indicates how many shares 111.988 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Guardant Health earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Guardant Health's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Guardant Health’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Guardant Health's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Guardant Health.

Guardant Health latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.77 -0.88  (-14.73 %)2024 Q3
6/30/2024-0.76 -0.84  (-9.83 %)2024 Q2
3/31/2024-0.88 -0.94  (-7.13 %)2024 Q1
12/31/2023-0.89 -0.85  (4.53 %)2023 Q4
9/30/2023-0.97 -0.73  (24.92 %)2023 Q3
6/30/2023-1.2 -0.67  (44.32 %)2023 Q2
3/31/2023-1.34 -1.3  (2.99 %)2023 Q1
12/31/2022-1.4 -1.36  (2.75 %)2022 Q4
9/30/2022-1.27 -1.41  (-10.38 %)2022 Q3
6/30/2022-1.22 -1.27  (-4.1 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Guardant Health stock

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

30

👫 Social

91

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees56
Percentage of women in management
Percentage of Asian employees39.4
Share of Asian management
Percentage of Hispanic/Latino employees9.2
Hispano/Latino Management share
Percentage of Black employees4
Black Management Share
Percentage of white employees39.9
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Guardant Health shareholders

%
Name
Stocks
Change
Date
9.39792 % The Vanguard Group, Inc.11,611,134197,4006/30/2024
6.81289 % BlackRock Institutional Trust Company, N.A.8,417,323-217,9376/30/2024
4.93184 % Baillie Gifford & Co.6,093,286-138,8186/30/2024
4.85679 % Deep Track Capital LP6,000,5601,500,5609/30/2024
3.61693 % Capital International Investors4,468,723645,7846/30/2024
3.04374 % Eventide Asset Management, LLC3,760,538-418,8946/30/2024
3.03448 % Temasek Holdings Pte. Ltd.3,749,102-362,0706/30/2024
2.83994 % Wellington Management Company, LLP3,508,7433,508,7436/30/2024
2.66362 % Citadel Advisors LLC3,290,897500,3596/30/2024
2.53485 % Cadian Capital Management LP3,131,808-2,660,9716/30/2024
1
2
3
4
5
...
10

Guardant Health Executives and Management Board

Mr. John Saia

(50)
Guardant Health Chief Legal Officer, Corporate Secretary
Compensation 6.02 M

Mr. Christopher Freeman

(49)
Guardant Health Chief Commercial Officer
Compensation 3.97 M

Dr. Craig Eagle

(56)
Guardant Health Chief Medical Officer
Compensation 3.62 M

Mr. Michael Bell

(54)
Guardant Health Chief Financial Officer
Compensation 1.98 M

Mr. Steven Krognes

(54)
Guardant Health Independent Director
Compensation 725,146
1
2
3

Most common questions regarding Guardant Health

What values and corporate philosophy does Guardant Health represent?

Guardant Health Inc represents values of innovation, precision, and compassion in the field of comprehensive cancer care. As a leading precision oncology company, Guardant Health is committed to transforming cancer treatment through advanced diagnostics and therapeutics. With their liquid biopsy technology, they aim to provide personalized and non-invasive genomic profiling, aiding in early cancer detection and treatment decisions. Guardant Health's corporate philosophy revolves around collaboration and empowerment, as they strive to improve patient outcomes and ease the burden of cancer. By combining cutting-edge technology with compassionate care, Guardant Health Inc epitomizes a commitment to revolutionizing cancer care for a better future.

In which countries and regions is Guardant Health primarily present?

Guardant Health Inc is primarily present in the United States.

What significant milestones has the company Guardant Health achieved?

Some significant milestones achieved by Guardant Health Inc include the successful completion of their initial public offering (IPO) in October 2018, generating over $235 million in funding. Additionally, the company's liquid biopsy test, Guardant360, received breakthrough device designation from the U.S. FDA in 2018, highlighting its potential impact in cancer diagnostics. Guardant Health Inc also expanded its global presence by establishing partnerships with several pharmaceutical companies and collaborating with research institutions. These achievements demonstrate Guardant Health Inc's growth as a leader in precision oncology, offering innovative solutions and advancing cancer care.

What is the history and background of the company Guardant Health?

Guardant Health Inc. is a leading precision oncology company specializing in blood-based cancer tests. Founded in 2012, Guardant Health has rapidly grown to become a prominent player in the field of liquid biopsy. The company's breakthrough technology, Guardant360, enables comprehensive genomic profiling of solid tumors through a simple blood draw, facilitating personalized treatment decisions for cancer patients. With an extensive database of over 120,000 patients, Guardant Health Inc. is revolutionizing cancer diagnostics and therapy selection. Guardant Health is committed to advancing precision oncology and improving patient outcomes through its innovative genomic testing solutions.

Who are the main competitors of Guardant Health in the market?

The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.

In which industries is Guardant Health primarily active?

Guardant Health Inc is primarily active in the healthcare industry.

What is the business model of Guardant Health?

The business model of Guardant Health Inc. revolves around precision oncology and liquid biopsy. As a leading precision oncology company, Guardant Health develops and commercializes blood tests that can detect and monitor cancer. By analyzing the genetic alterations in circulating tumor DNA, Guardant Health enables oncologists to make more informed treatment decisions for their patients. The company's comprehensive liquid biopsy platform, including their flagship product Guardant360, provides a non-invasive alternative to traditional tissue biopsies. With their commitment to advancing cancer care, Guardant Health Inc. aims to improve patient outcomes through their innovative molecular diagnostics and therapeutic development solutions.

What is the P/E ratio of Guardant Health 2025?

The Guardant Health P/E ratio is -11.62.

What is the P/S ratio of Guardant Health 2025?

The Guardant Health P/S ratio is 4.97.

What is the Quality Investing of Guardant Health?

The Quality Investing for Guardant Health is 4/10.

What is the revenue of Guardant Health 2025?

The expected Guardant Health revenue is 871.59 M USD.

How high is the profit of Guardant Health 2025?

The expected Guardant Health profit is -372.63 M USD.

What is the business model of Guardant Health

Guardant Health Inc. is a leading company in the field of liquid biopsy and cancer early detection. The company offers innovative solutions and technologies for cancer prevention, diagnosis, and therapy. Guardant Health has two different business units: Guardant360 and GuardantOMNI. Both divisions differ in their target audience and product portfolio. Guardant360 is a blood test that captures the DNA profile of tumor cells, thereby identifying the genetic fingerprint of cancer cells. This allows for more precise and faster diagnosis. The technology of Guardant360 is used by doctors and oncologists to analyze the genetic profiles of tumor cells in real-time and develop the best possible therapy for the patient. GuardantOMNI is a comprehensive cancer genomic test that covers over 500 genes, enabling an accurate diagnosis. GuardantOMNI is used by pharmaceutical companies to develop personalized therapies and drugs. Guardant Health is committed to advancing precision medicine in the field of cancer diagnostics and therapy. By using liquid biopsy technologies, doctors and oncologists can make accurate diagnoses and offer targeted therapy. Guardant Health has also partnered with renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Amgen to develop personalized therapies. In addition, the company has conducted its own clinical study on cancer early detection, and further studies are planned. The business model of Guardant Health is based on selling its products and solutions to medical facilities such as hospitals, laboratories, and oncologists. The company also generates revenue through partnerships with pharmaceutical companies and participation in clinical trials. Overall, Guardant Health is a company with a promising business model based on the use of liquid biopsy technologies. The company aims to revolutionize cancer diagnostics and therapy and offer personalized medicine. The wide portfolio of solutions and products from Guardant Health allows it to cater to the needs of doctors, oncologists, and pharmaceutical companies.

What is the Guardant Health dividend?

Guardant Health pays a dividend of 0 USD distributed over payouts per year.

How often does Guardant Health pay dividends?

The dividend cannot currently be calculated for Guardant Health or the company does not pay out a dividend.

What is the Guardant Health ISIN?

The ISIN of Guardant Health is US40131M1099.

What is the Guardant Health WKN?

The WKN of Guardant Health is A2N5RY.

What is the Guardant Health ticker?

The ticker of Guardant Health is GH.

How much dividend does Guardant Health pay?

Over the past 12 months, Guardant Health paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Guardant Health is expected to pay a dividend of 0 USD.

What is the dividend yield of Guardant Health?

The current dividend yield of Guardant Health is .

When does Guardant Health pay dividends?

Guardant Health pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Guardant Health?

Guardant Health paid dividends every year for the past 0 years.

What is the dividend of Guardant Health?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Guardant Health located?

Guardant Health is assigned to the 'Health' sector.

Wann musste ich die Aktien von Guardant Health kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Guardant Health from 1/11/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/11/2025.

When did Guardant Health pay the last dividend?

The last dividend was paid out on 1/11/2025.

What was the dividend of Guardant Health in the year 2024?

In the year 2024, Guardant Health distributed 0 USD as dividends.

In which currency does Guardant Health pay out the dividend?

The dividends of Guardant Health are distributed in USD.

All fundamentals about Guardant Health

Our stock analysis for Guardant Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guardant Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.